Anti-Inflammatory Drug Therapy in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis of Prospective Randomized and Placebo-Controlled Trials
Journal of Clinical Medicine · 20.06.2023 · 12 (12) · 4165
DOI: 10.3390/jcm12124165 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.06.2023. Verfasst von Johannes Wach und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University Hospital Leipzig, 04103 Leipzig, Germany. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Emerging evidence suggests that neuroinflammation may play a potential role in aneurysmal subarachnoid hemorrhage (aSAH). We aim to analyze the influence of anti-inflammatory therapy on survival and outcome in aSAH. Eligible randomized placebo-controlled prospective trials (RCTs) were searched in PubMed until March 2023. After screening the available studies for inclusion and exclusion criteria, we strictly extracted the main outcome measures. Dichotomous data were determined and extracted by odds ratio (OR) with 95% confidence intervals (CIs). Neurological outcome was graded using the modified Rankin Scale (mRS). We created funnel plots to analyze publication bias. From 967 articles identified during the initial screening, we included 14 RCTs in our meta-analysis. Our results illustrate that anti-inflammatory therapy yields an equivalent probability of survival compared to placebo or conventional management (OR: 0.81, 95% CI: 0.55–1.19, p = 0.28). Generally, anti-inflammatory therapy trended to be associated with a better neurologic outcome (mRS ≤ 2) compared to placebo or conventional treatment (OR: 1.48, 95% CI: 0.95–2.32, p = 0.08). Our meta-analysis showed no increased mortality form anti-inflammatory therapy. Anti-inflammatory therapy in aSAH patients tends to improve the neurological outcome. However, multicenter, rigorous, designed, prospective randomized studies are still needed to investigate the effect of fighting inflammation in improving neurological functioning after aSAH.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, University Hospital Leipzig, 04103 Leipzig, Germany.
ORCID-Profile: Johannes Wach
Zitieren
APA
Wach, J., Vychopen, M., Güresir, A., & Güresir, E. (2023). Anti-Inflammatory Drug Therapy in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis of Prospective Randomized and Placebo-Controlled Trials. Journal of Clinical Medicine, 12(12), 4165. https://doi.org/10.3390/jcm12124165
Vancouver
Wach J, Vychopen M, Güresir A, Güresir E. Anti-Inflammatory Drug Therapy in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis of Prospective Randomized and Placebo-Controlled Trials. Journal of Clinical Medicine. 2023;12(12):4165. doi:10.3390/jcm12124165
BibTeX
@article{Wach2023,
author = {Wach, Johannes and Vychopen, Martin and Güresir, Agi and Güresir, Erdem},
title = {Anti-Inflammatory Drug Therapy in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis of Prospective Randomized and Placebo-Controlled Trials},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {12},
pages = {4165},
doi = {10.3390/jcm12124165}
}
EUVIMED